Loading...

APUS APIMEDS PHARMACEUTICALS US INC Management Changes 8-K Filing

PMDS

PS

APIMEDS PHARMACEUTICALS US INC

(APUS)

2025 8-K

New CEO Appointment

Settlement Agreement

Delisting Notice

Filings Delay Notification

Stockholder Consent Nullified

Board Changes Invalidated

Board Restructuring

Stock Split Announcement

Director Resignations

Merger Amendment Notice

Merger Agreement

CEO Salary Increase

Bylaw Amendment

Investor Meetings

Debt Restructuring

External Links:

On October 15, 2025, Apimeds Pharmaceuticals US, Inc. amended its bylaws to enable shareholder actions by written consent.

AI Assistant

APIMEDS PHARMACEUTICALS US INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.